Targeting the protein kinase C family: are we there yet?

被引：317

作者：

Mackay, Helen J.

Twelves, Christopher J. ^{[1
]}

机构：

[1] Univ Bradford, Inst Canc Therapeut, Bradford BD7 1DP, W Yorkshire, England

[2] Univ Toronto, Princess Margaret Hosp, Dept Haematol & Med Oncol, Toronto, ON, Canada

来源：

NATURE REVIEWS CANCER | 2007年 / 7卷 / 07期

关键词：

BREAST-CANCER CELLS; ANTISENSE OLIGONUCLEOTIDE APRINOCARSEN; SIGNAL-TRANSDUCTION PATHWAYS; GLYCOGEN-SYNTHASE KINASE-3; PHASE-I TRIAL; BETA-II; MULTIDRUG-RESISTANCE; ALPHA EXPRESSION; GROWTH-FACTOR; BRYOSTATIN;

D O I：

10.1038/nrc2168

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Protein kinase C (PKC) comprises a family of serine/ threonine kinases that are involved in the transduction of signals for cell proliferation, differentiation, apoptosis and angiogenesis. Unsurprisingly, disruption of PKC regulation is implicated in tumorigenesis and drug resistance. PKC function is complex in this context owing to the differing roles of individual isozymes within the cell and across tumour types. Therapeutically targeting PKC isozymes is not new; however, with many of the early PKC inhibitor cytotoxic drug combinations being discarded at the phase II level, and recent phase III studies in non-small-cell lung cancer proving negative, what's going wrong?

引用

页码：554 / 562

页数：9

共 132 条

[1] What is the right dose? The elusive optimal biologic dose in phase I clinical trials [J].